Romero Frederico R, Xavier Luiz Ricardo T P, Romero Antonio W, Almeida Rui Manuel S de, Matias Jorge Eduardo F, Tambara Filho Renato
Hospital Policlínica Cascavel, Cascavel, PR, Brazil.
Faculdade Assis Gurgacz (FAG), Cascavel, PR, Brazil.
Int Braz J Urol. 2015 Mar-Apr;41(2):360-6. doi: 10.1590/S1677-5538.IBJU.2015.02.25.
To evaluate if the different results of prostate cancer risk between black and white Brazilian men may be associated with the varying methodology used to define participants as either Blacks or Whites.
We evaluated median PSA values, rate of PSA level ≥ 4.0 ng/ mL, indications for prostate biopsy, prostate cancer detection rate, biopsy/cancer rate, cancer/biopsy rate, and the relative risk of cancer between blacks versus whites, blacks versus non-blacks (browns and whites), non-whites (browns and blacks) versus whites, African versus non-African descendants, and African descendants or blacks versus non-African descendants and non-blacks.
From 1544 participants, there were 51.4% whites, 37.2% browns, 11.4% blacks, and 5.4% African descendants. Median PSA level was 0.9 ng/mL in whites, browns, and non-African descendants, compared to 1.2 ng/mL in blacks, and African descendants or blacks, and 1.3 ng/mL in African descendants. Indications for prostate biopsy were present in 16.9% for African descendants, 15.9% of black, 12.3% of white, 11.4% for non-African descendants, and 9.9% of brown participants. Prostate cancer was diagnosed in 30.3% of performed biopsies: 6.2% of African descendants, 5.1% of blacks, 3.3% of whites, 3.0% of non-African descendants, and 2.6% of browns.
Median PSA values were higher for Blacks versus Whites in all classification systems, except for non-white versus white men. The rate of prostate biopsy, prostate cancer detection rate, and relative risk for cancer was increased in African descendants, and African descendants or blacks, compared to non-African descendants, and non-African descendants and non-blacks, respectively.
评估巴西黑人和白人男性前列腺癌风险的不同结果是否可能与用于将参与者定义为黑人或白人的不同方法有关。
我们评估了前列腺特异性抗原(PSA)的中位数、PSA水平≥4.0 ng/mL的比率、前列腺活检指征、前列腺癌检出率、活检/癌症率、癌症/活检率,以及黑人与白人、黑人与非黑人(棕色人种和白人)、非白人(棕色人种和黑人)与白人、非洲后裔与非非洲后裔,以及非洲后裔或黑人与非非洲后裔和非黑人之间的癌症相对风险。
在1544名参与者中,白人占51.4%,棕色人种占37.2%,黑人占11.4%,非洲后裔占5.4%。白人、棕色人种和非非洲后裔的PSA中位数水平为0.9 ng/mL,而黑人、非洲后裔或黑人的PSA中位数水平为1.2 ng/mL,非洲后裔的PSA中位数水平为1.3 ng/mL。非洲后裔中16.9%、黑人中15.9%、白人中12.3%、非非洲后裔中11.4%以及棕色人种参与者中9.9%有前列腺活检指征。在进行的活检中,30.3%被诊断为前列腺癌:非洲后裔中为6.2%,黑人中为5.1%,白人中为3.3%,非非洲后裔中为3.0%,棕色人种中为